MedMira's Biosensor Division to Collaborate with National Research Council on Breast Cancer Research

17-Nov-2006

MedMira Inc. announced that it has entered into a collaborative agreement with the National Research Council of Canada (NRC), through its biosensor division, Maple BioSciences. The agreement will allow NRC to work with Maple BioSciences on the discovery and validation of breast cancer biomarkers. The project will commence when the final agreement and details are completed in early 2007.

The NRC/Maple Biosciences partnership shall bring together research and the mapleTWO technology resulting in advanced diagnostics and additional accuracy in the classification of the various breast cancer development stages. mapleTWO, based on the SKN (scanning Kelvin nanoprobe) technology, is a sensitive tool for detecting the biomolecular interactions that form the heart of clinical diagnostics.

Other news from the department science

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures
View topic world

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures